Trilucent breast implants
This article was originally published in The Gray Sheet
Executive Summary
Product liability suit filed Aug. 10 in California federal court related to development, manufacture or sale of the "potentially dangerous" soy-based breast implants names Inamed, AEI (formerly Collagen Aesthetics), Cohesion Technologies, TUV, LipoMatrix, and Washington University, St. Louis as defendants. Filed by Miami attorney Jeffrey Herman of the law firm Herman & Mermelstein, the suit follows a June advisory issued by Britain's Medical Devices Agency after reports of rupture and toxicity were linked to the implants (1"The Gray Sheet" June 12, p. 12). Roughly 9,000 procedures were performed in Europe between 1995-1999; about 2,000 woman have had their implants removed
You may also be interested in...
Trilucent Breast Implants Should Be Explanted - UK Medical Devices Agency
Mutagenicity studies conducted by Collagen Aesthetics' LipoMatrix unit on the safety of Trilucent breast implants containing a soybean oil filler material failed to take into account the absence of aged characterized oil and the use of extracts, according to an advisory group to the UK's Medical Devices Agency (MDA).
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.